Our portfolio

Descriptor

Innovative technology to identify small molecule drug candidates for CNS disorders. Pipeline includes 4 programs with the lead product in several phase II clinical trials.

A unique partnership model for the creation and acceleration of cardiovascular devices into the market.

Medical device Company focused on cardiac assist devices. Developed the IMPELLA systems, which are minimally invasive ventricle assist devices.

Acorda Therapeutics® is a biotechnology company whose mission is to develop and market therapies to restore neurological function in people with spinal cord injury (SCI), multiple sclerosis (MS) and related conditions of the nervous system

Developing 'best in class' small molecule drugs for Type II diabetes and Osteoarthritis/inflammation based diseases. Apart from the lead product (DPPIV inhibitor in phase I clinical trials) Alantos has 5 programs in various stages of preclinical development.

Combines an in-licencing and M&A driven strategy to commercialize research carried out by the Medical Research Council (MRC) Human Reproductive Sciences Unit (HRSU) in Edinburgh, Scotland. Besides 2 marketed products Ardana has a number of compounds in clinical development.

Uses two technology platforms to identify and produce low cost antibody analogues based on naturally occurring human proteins. Borean's lead product is a TNF antagonist undergoing preclinical trials for rheumatoid arthritis. Borean also has further research programmes in Crohn's disease, HIV and cancer.

CBD developed gene and cell therapy products with focus on delivery of FVIII bloodclotting proteins.

Antibody discovery and development platform combined with the PER.C6 protein production plaform. The original investment was made in UbiSys, an antibody discovery company, which merged with Introgen to form Crucell, now a vaccine company.

Flowmedica has developed novel, proprietary, minimally invasive intravascular systems for implementing targeted renal therapy. Three infusion systems have been developed and provide an alternative to the standard delivery methods of systemic intravenous infusion to address kidney dysfunction related to a number of diseases.

Developing and commercializing drugs for the treatment of ocular diseases, with a special focus on retinal pathologies. Fovea has multiple clinical programs ongoing in retinal degeneration, macular edema, glaucoma, and inflammation.

Forbion's initial investment was in Cambridge Drug Discovery, which was sold to Biofocus which in turn was sold to Galapagos. CDD focus was on discovery of novel SMEs against a variety of CNS targets. Galapagos operates service and in-house drug discovery divisions.

Development company focused on secondary tissue damage, specifically reperfusion injury

GLYCART biotechnology AG is active in the research and development of engineered antibody-based products with higher efficacy for the treatment of unmet clinical needs such as cancer

Discovery and development of immunosuppresive drugs from a proprietary library of (proteins from) pathogens.

Non-invasive Functional Electrical Stimulation of Neurons in partially paralyses patients. Ness is now part of Bioness and changed its name to Bioness Neuromodulation.

Discovery and development of antibodies (fragments) against fungal and bacterial infections. Neutec went public in 2002 and was acquired by Novartis Pharma in 2006.

Recombinant production of vaccines and other proteins using a novel yeast system. After the acquistion by Berna Biotech, Berna itself was acquired by Crucell in 2006. Later the production unit was spun out from Crucell and was after a short period of independence acquired by Dynavax

Integrated drug eluting stent (DES) company developing next-generation solutions for restenosis and other cardiovascular clinical applications. X-Cell’s lead program uses 17-ß-estradiol on DES which enhances endothelial growth to help combat sub-acute thrombosis.